Latest News
2019.01.25
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.

Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, often manifesting at the advanced stage when cure is no longer possible. The discrepancy between preclinical findings and clinical outcome in HCC is well-recognized. So far, sorafenib is the only targeted therapy approved as first-line therapy for patients with advanced HCC. There is an urgent need for improved preclinical models for the development of HCC-targeted therapies. Patient-derived xenograft (PDX) tumor models have been shown to closely recapitulate human tumor biology and predict patient drug response. However, the use of PDX models is currently limited by high costs and low throughput. In this study, we engineered in vitro conditions conducive for the culture of HCC-PDX organoids derived from a panel of 14 different HCC-PDX lines through the use of a three-dimensional macroporous cellulosic sponge system. To validate the in vitro HCC-PDX models, both in vivo and in vitro HCC-PDX models were subjected to whole exome sequencing and RNA-sequencing. Correlative studies indicate strong concordance in genomic and transcriptomic profiles as well as intra-tumoral heterogeneity between each matched in vitro-in vivo HCC-PDX pairs. Furthermore, we demonstrate the feasibility of using these in vitro HCC-PDX models for drug testing, paving the way for more efficient preclinical studies in HCC drug development.

About PISHON

en加樂生醫股份有限公司是一家擁有全球先進3D細胞培養支架研發、生產專利技術並提供一站式體外精准醫療服務解決方案,專注於精准化醫療的科學技術公司。從目前全球及中國大陸的醫療市場發展和技術資源的角度考量,臺灣公司將把未來發展重點放在中國大陸。

2016年進軍精準醫療 建立體外藥篩平臺、結直腸癌、肝癌、乙肝體外藥測模型,並與醫院簽訂開發計畫

2015年體外肝毒理測試、原代細胞培養、癌細胞系與腫瘤3維模型建立及藥篩試驗 

2014年可降解植物性3D細胞培養支架開發成功

2013年Cellusponge表面改良定制化服務

2012年推出3D細胞培養支架 Cellusponge

2011年完成獨家專利技術轉移,建立生產線及細胞培養實驗室

 

主要商品/服務項目

 

 

腫瘤篩查用藥指導及監測一站式服務項目

 

加樂生醫公司擁有先進的三維細胞培養系統,為體外細胞培養的領域,帶來革命性的改變。近年來,被廣泛應用在臨床前藥物篩選、新藥研發與腫瘤模型的建立等領域。公司自2016年積極投入OncoTreat®;平台的開發,建立病人來源的腫瘤類器官培養,用以化療藥物的藥物敏感試驗,提供臨床用藥指導參考數據。此平台與PDX(動物藥敏平台)相較,將大幅縮短檢測週期,由平均5個月縮短到14-21工作日,同時高通量的檢測,為患者節約檢測成本,減輕患者經濟和精神負擔。

 

2016年更引進PrimoCatcher®;平台,結合正、負向篩選的優點,提供高準確的循環腫瘤細胞定量計數服務,達到早期篩查、手術評估與長期追蹤的效果。此平台技術,經長庚醫院臨床實證,與病人術後發展呈現正相關,並發表於國際期刊。結合OncoTreat®;與PrimoCatcher®;平台,我們建立的實驗室推出腫瘤篩查用藥指導及監測一站式服務,服務對象函括亞健康族群及治療前的早其發現、治療中的療效評估與治療後的癒後判斷與定期追縱。

 

PDOService
Patient Derived Organoid
CROService
Contract Research Organization
Product

We provide professional material and medium for 3D cell culture

  • 3F, No.33, Dexing W. Rd., Shilin Dist.,
    Taipei City 111, Taiwan (R.O.C.)
  • +886-2-2834-3959 、 +886-2-2832-2379
  • +886-2-2831-8169
TOP